Table 1.
Baseline patient characters
| Variable | No diabetes (n = 134) | Diabetes (n = 67) | p value |
|---|---|---|---|
| Age, years | 48.8 ± 13.5 | 50.1 ± 13.8 | 0.53 |
| Male, n | 78 (58.2%) | 41 (61.2%) | 0.69 |
| Body mass index, kg/m2 | 25.9 ± 3.9 | 25.6 ± 3.7 | 0.69 |
| Family history of HCM or SCD, n | 18 (13.4%) | 15 (22.4%) | 0.11 |
| Heart rate, beats/min | 72.2 ± 9.3 | 72.7 ± 8.5 | 0.71 |
| BNP, pg/mL | 1379.9 (636.3–2342.4) | 1605.5 (573.7–2726.3) | 0.71 |
| Creatinine, umol/L | 77.3 ± 13.4 | 76.8 ± 14.8 | 0.83 |
| Glomerular filtration rate, ml/min | 99.8 ± 20.2 | 93.7 ± 18.5 | 0.04 |
| Hs-CRP, mg/L | 0.97 (0.40–1.80) | 1.30 (0.56–2.28) | 0.04 |
| LDL, mmol/L | 2.6 ± 0.9 | 2.5 ± 0.6 | 0.31 |
| HDL, mmol/L | 1.2 ± 0.5 | 1.16 ± 0.3 | 0.63 |
| Comorbidities | |||
| Hypertension, n | 54 (40.3%) | 28 (41.8%) | 0.84 |
| Hyperlipemia, n | 28 (20.9%) | 15 (22.4%) | 0.81 |
| Clinical presentation | |||
| Chest pain, n | 35 (26.1%) | 20 (29.9%) | 0.58 |
| Palpitation, n | 11 (8.2%) | 8 (11.9%) | 0.39 |
| Syncope, n | 14 (10.4%) | 8 (11.9%) | 0.75 |
| Atrial fibrillation, n | 16 (11.9%) | 19 (28.4%) | 0.004 |
| Echocardiographic indices | |||
| LVEDD, mm | 41.8 ± 5.7 | 41.5 ± 4.5 | 0.70 |
| IVST, mm | 20.3 ± 5.6 | 20.0 ± 5.8 | 0.74 |
| Posterior wall, mm | 11.9 ± 2.4 | 12.2 ± 2.9 | 0.56 |
| LVEF, % | 71.4 ± 5.6 | 71.3 ± 5.4 | 0.94 |
| IVST ≥ 30 mm, n | 11 (8.2%) | 4 (6.0%) | 0.57 |
| Moderate or severe MR | 24 (17.9%) | 7 (10.4%) | 0.17 |
| Medical therapy | |||
| Beta-blockers, n | 99 (73.9%) | 50 (74.6%) | 0.91 |
| Calcium-channel blockers, n | 7 (5.2%) | 7 (10.4%) | 0.17 |
| ACEI/ARB, n | 17 (12.7%) | 8 (11.9%) | 0.88 |
| Statins, n | 14 (10.4%) | 11 (16.4%) | 0.23 |
| Insulin, n | – | 19 (28.4%) | – |
| Metformin, n | – | 39 (58.2%) | – |
| Acarbose, n | – | 12 (17.9%) | – |
Values are presented as percentage, mean ± SD, or median (interquartile range) when appropriate
IVST interventricular septal thickness, HCM hypertrophic myocardiopathy; SCD sudden cardiac death, NYHA New York Heart Association, BNP brain natriuretic peptide, LVEF left ventricular ejection fraction, LDL low density lipoprotein, HDL high density lipoprotein, LVEDD left ventricular end diastole diameter, LVOT left ventricular outflow tract, MR mitral regurgitation, ACEI/ARB angiotensin-converting enzyme inhibitor or angiotensin receptor blocker